Quick Answer
NEUROCRINE BIOSCIENCES INC reported Cash and Equivalents of $713.00 million for fiscal year 2025.
NEUROCRINE BIOSCIENCES INC Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $713.00M | +206.0% |
| 2024 | $233.00M | -7.2% |
| 2023 | $251.10M | -4.5% |
| 2022 | $262.90M | -22.9% |
| 2021 | $340.80M | +82.1% |
| 2020 | $187.10M | +66.6% |
| 2019 | $112.30M | -20.8% |
| 2018 | $141.71M | -44.4% |
| 2017 | $254.71M | +205.9% |
| 2016 | $83.27M | +12.2% |
| 2015 | $74.19M | +139.2% |
| 2014 | $31.01M | -30.8% |
| 2013 | $44.79M | -29.7% |
| 2012 | $63.75M | +27.2% |
| 2011 | $50.11M | -7.3% |
| 2010 | $54.05M | +44.8% |
| 2009 | $37.33M | -45.5% |
| 2008 | $68.47M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $340.20M | -2.5% | +28.9% |
| June 30, 2025 | $264.00M | +89.0% | +36.0% |
| March 31, 2025 | $194.10M | -51.0% | -16.7% |
| December 31, 2024 | $233.00M | -7.2% | -33.3% |
| September 30, 2024 | $349.10M | +18.9% | +149.9% |
| June 30, 2024 | $139.70M | -12.8% | -64.7% |
| March 31, 2024 | $396.30M | +281.8% | +57.8% |
| December 31, 2023 | $251.10M | -4.5% | -14.5% |
- NEUROCRINE BIOSCIENCES INC showed an increase of +206.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2008–2025 period, NEUROCRINE BIOSCIENCES INC’s cash and equivalents has grown by 941.4% (from $68.47 million to $713.00 million).
- The most recent figure is from NEUROCRINE BIOSCIENCES INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: